David M Loesch
Overview
Explore the profile of David M Loesch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
531
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pierobon M, Robert N, Northfelt D, Jahanzeb M, Wong S, Hodge K, et al.
Mol Oncol
. 2021 Aug;
16(1):104-115.
PMID: 34437759
This prospective phase II clinical trial (Side Out 2) explored the clinical benefits of treatment selection informed by multi-omic molecular profiling (MoMP) in refractory metastatic breast cancers (MBCs). Core needle...
2.
Weiss G, Hoff B, Whitehead R, Sangal A, Gingrich S, Penny R, et al.
Onco Targets Ther
. 2015 May;
8:959-67.
PMID: 25960669
Background: It is widely acknowledged that there is value in examining cancers for genomic aberrations via next-generation sequencing (NGS). How commercially available NGS platforms compare with each other, and the...
3.
Jameson G, Petricoin E, Sachdev J, Liotta L, Loesch D, Anthony S, et al.
Breast Cancer Res Treat
. 2014 Sep;
147(3):579-88.
PMID: 25209003
The primary objective was to determine if multi-omic molecular profiling (MMP) informed selection of approved cancer treatments could change the clinical course of disease for patients with previously treated metastatic...
4.
Von Hoff D, Stephenson Jr J, Rosen P, Loesch D, Borad M, Anthony S, et al.
J Clin Oncol
. 2010 Oct;
28(33):4877-83.
PMID: 20921468
Purpose: To compare the progression-free survival (PFS) using a treatment regimen selected by molecular profiling (MP) of a patient's tumor with the PFS for the most recent regimen on which...
5.
Fidias P, Dakhil S, Lyss A, Loesch D, Waterhouse D, Bromund J, et al.
J Clin Oncol
. 2008 Dec;
27(4):591-8.
PMID: 19075278
Purpose: Gemcitabine plus carboplatin (GC) is active as front-line treatment for advanced non-small-cell lung cancer (NSCLC). For patients without progression, timing of second-line chemotherapy for optimum clinical benefit remains uncertain....
6.
Gralla R, Edelman M, Detterbeck F, Jahan T, Loesch D, Limentani S, et al.
Support Care Cancer
. 2008 Sep;
17(3):307-13.
PMID: 18781341
Background: The assessment of the impact of neoadjuvant therapy on quality of life (QL) has rarely been prospectively planned and evaluated, although validated QL instruments are available-such as the Lung...
7.
Detterbeck F, Socinski M, Gralla R, Edelman M, Jahan T, Loesch D, et al.
J Thorac Oncol
. 2008 Jan;
3(1):37-45.
PMID: 18166839
Background: Surgical resection alone remains suboptimal for patients with early-stage (I or II) non-small cell lung cancer. Two similar randomized phase II trials were conducted to define an active preoperative...
8.
Berry W, Hathorn J, Dakhil S, Loesch D, Jackson D, Gregurich M, et al.
Clin Prostate Cancer
. 2004 Oct;
3(2):104-11.
PMID: 15479494
This study was conducted to determine the similarity of response rates and safety produced by weekly paclitaxel with or without oral estramustine in patients with metastatic hormone-refractory prostate cancer. Between...
9.
Loesch D, Asmar L, Canfield V, Parker G, Hynes H, Ellis P, et al.
Breast Cancer Res Treat
. 2003 Feb;
77(2):115-23.
PMID: 12602910
Purpose: This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer. Patients And Methods: The study...